PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT

被引：0
|
作者：
Harisseh, Rania
Finnegan, Beth
Thomas, Stephane
Legry, Vanessa
Hum, Dean
Marbury, Thomas C.
Perry, Robert G.
Wyatt, David J.
Addy, Carol
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1503
引用
收藏
页码：S1391 / S1391
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
    Halabi, Atef
    Maatouk, Haidar
    Siegler, Karl Ernst
    Faisst, Nadja
    Hinrichsen, Holger
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 290 - 296
  • [2] Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
    Jamieson, Brian D.
    Ciric, Sabrina
    Fernandes, Prabhavathi
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4379 - 4386
  • [3] Ragaglitazar: Pharmacokinetics and safety in subjects with or without hepatic impairment
    Lundholm, H
    Pabst, G
    Skrumsager, BK
    Horak, J
    [J]. DIABETES, 2002, 51 : A489 - A489
  • [4] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SELADELPAR IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Mao, Z.
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1320 - S1320
  • [5] Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment
    Xin, Yan
    Kawashima, Jun
    Weng, Winnie
    Kwan, Ellen
    Tarnowski, Thomas
    Silverman, Jeffrey A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 522 - 532
  • [6] Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment
    Mao, Lily
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E402 - E402
  • [7] Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
    Custodio, Joseph M.
    Rhee, Martin
    Shen, Gong
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) : 2564 - 2569
  • [8] Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers
    Zhao, QY
    Iyer, GR
    Verhaeghe, T
    Truyen, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04): : 428 - 436
  • [9] PHARMACOKINETICS AND SAFETY OF TENOFOVIR ALAFENAMIDE IN SUBJECTS WITH SEVERE HEPATIC IMPAIRMENT
    Custodio, J. M.
    Ma, G.
    Cuvin, J.
    Ting, L.
    Flaherty, J.
    Zack, J. Z.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S594 - S595
  • [10] Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment
    Erik Mogalian
    Diana M. Brainard
    Anu Osinusi
    Lisa Moorehead
    Bernard Murray
    Kah Hiing John Ling
    Robert Perry
    Craig Curtis
    Eric Lawitz
    Kenneth Lasseter
    Thomas Marbury
    Anita Mathias
    [J]. Clinical Pharmacokinetics, 2018, 57 : 1449 - 1457
12345